Six main classes of bDMARD and tsDMARDs targeting TNFi, CTLA4, interleukin (IL)-1, IL-6, Janus kinase (JAK), and CD20 are used to treat RA. This evidence concerns the gene IL6 and rheumatoid arthritis.